BRPI0515449A2 - polimorfos de inibidor de cisteÍna protease n-(1-cianociclopropil)-3-ciclopropilmetanossulfonil -2 (r)-[2,2,2-trifluoro-1(s)-(4-flurofenil) etilamino] propionamida - Google Patents

polimorfos de inibidor de cisteÍna protease n-(1-cianociclopropil)-3-ciclopropilmetanossulfonil -2 (r)-[2,2,2-trifluoro-1(s)-(4-flurofenil) etilamino] propionamida

Info

Publication number
BRPI0515449A2
BRPI0515449A2 BRPI0515449-9A BRPI0515449A BRPI0515449A2 BR PI0515449 A2 BRPI0515449 A2 BR PI0515449A2 BR PI0515449 A BRPI0515449 A BR PI0515449A BR PI0515449 A2 BRPI0515449 A2 BR PI0515449A2
Authority
BR
Brazil
Prior art keywords
trifluoro
fluorophenyl
cyanocyclopropyl
propionamide
ethylamino
Prior art date
Application number
BRPI0515449-9A
Other languages
English (en)
Inventor
Sheila M Zipfel
Soon H Woo
Donglai Yang
Simon Bates
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/943,768 external-priority patent/US7547701B2/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Priority claimed from PCT/US2005/033074 external-priority patent/WO2006034006A1/en
Publication of BRPI0515449A2 publication Critical patent/BRPI0515449A2/pt

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

POLIMORFOS DE INIBIDOR DE CISTEÍNA PROTEASE N-(1-CIANOCICLOPROPIL)-3-CICLOPROPILMETANOSSULFO- NIL-2 (R)-[2,2,2-TRIFLUORO-1(S)-(4-FLUOROFENIL) ETILAMINO] PRO- PIONAMIDA. A presente invenção refere-se a polimorfos de N-(1-cianociclo- propil)-3-ciclopropilmetanossulfanil-2 (R)-[2 ,2,2-Trifluoro-1 (S)-(4-fluorofenil) etilamino] propionamida, métodos de uso dos mesmos para tratamento de uma doença mediada por catepsina S, composições farmacêuticas contendo tais polimorfos e processos para prepará-las.
BRPI0515449-9A 2004-09-17 2005-09-16 polimorfos de inibidor de cisteÍna protease n-(1-cianociclopropil)-3-ciclopropilmetanossulfonil -2 (r)-[2,2,2-trifluoro-1(s)-(4-flurofenil) etilamino] propionamida BRPI0515449A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/943,768 US7547701B2 (en) 2003-09-18 2004-09-17 Haloalkyl containing compounds as cysteine protease inhibitors
PCT/US2004/030442 WO2005028429A2 (en) 2003-09-18 2004-09-17 Haloalkyl containing compounds as cysteine protease inhibitors
US66424405P 2005-03-21 2005-03-21
PCT/US2005/033074 WO2006034006A1 (en) 2004-09-17 2005-09-16 Polymorphs of the cysteine protease inhibitor n- (1-cyanocyclopropyl)-3-cyclopropylmethansulfonyl-2 (r) - (2,2,2-trifluoro-1 (s) - (4-fluorophenyl) ethylamino) propionamide

Publications (1)

Publication Number Publication Date
BRPI0515449A2 true BRPI0515449A2 (pt) 2008-12-16

Family

ID=38325575

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515449-9A BRPI0515449A2 (pt) 2004-09-17 2005-09-16 polimorfos de inibidor de cisteÍna protease n-(1-cianociclopropil)-3-ciclopropilmetanossulfonil -2 (r)-[2,2,2-trifluoro-1(s)-(4-flurofenil) etilamino] propionamida

Country Status (5)

Country Link
BR (1) BRPI0515449A2 (pt)
IL (1) IL181791A0 (pt)
MX (1) MX2007003112A (pt)
NO (1) NO20071936L (pt)
ZA (1) ZA200703104B (pt)

Also Published As

Publication number Publication date
ZA200703104B (en) 2008-09-25
NO20071936L (no) 2007-06-12
IL181791A0 (en) 2007-07-04
MX2007003112A (es) 2007-05-21

Similar Documents

Publication Publication Date Title
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
CY1107839T1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
NO20083956L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
BRPI0212733B8 (pt) composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo
SE0301010D0 (sv) Novel compounds
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
CY1110214T1 (el) Μεθοδοι και ενδιαμεσα
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
CY1111480T1 (el) Αναστολεις πολυμερασης toy rna που εξαρταται απο to rna του ιου ηπατιτιδας c και συνθεσεις και θεραπευτικες αγωγες χρησιμοποιωντας αυτους
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
EA200400023A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтическое использование и материалы для их синтеза
BR0010555A (pt) Inibidores de neuraminidases
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0507052A (pt) inibidores de quìnase
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
NO20054787L (no) Indenderivater som farmasotiske midler

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]